Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2000
11/16/2000WO2000034331A3 Analogues of glp-1
11/16/2000WO2000034285A3 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
11/16/2000WO2000029015A3 INFLUENCING OF ANGIGENESIS USING CD66a
11/16/2000WO2000027377A3 Phosphinate peptide analogs for the treatment of fibrotic disorders
11/16/2000WO2000026370A3 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/16/2000WO2000023464A3 Zinc finger binding domains for gnn
11/16/2000WO2000020448A3 Nlk1 -interacting proteins
11/16/2000WO2000009103A3 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders
11/16/2000WO2000005375A9 Gbs toxin receptor
11/16/2000WO2000000158A3 Alkylamines and their precursors as specific modulators of human gamma-delta t cell function
11/16/2000WO2000000157A3 Use of tempo and tempo derivatives for inducing cell death
11/16/2000DE19921887A1 Synergistic ectoparasiticide combination for use in human or veterinary medicine, comprising cyclic depsipeptide and piperazine compound as potentiating agent
11/16/2000DE19921693A1 Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000DE19919149A1 Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere Of interferon alpha-2 derived peptide homodimers and peptide heterodimers
11/16/2000DE10021266A1 Hergestellte Artikel mit Phosphodiesterase-Inhibitor Produced with Article phosphodiesterase inhibitor
11/16/2000CA2373672A1 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation
11/16/2000CA2373442A1 14.beta.-h-sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments
11/16/2000CA2373348A1 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000CA2373182A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000CA2373178A1 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000CA2373121A1 Vector-mediated delivery of integrating transposon sequences
11/16/2000CA2373015A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000CA2373010A1 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
11/16/2000CA2372871A1 Novel nucleic acids and proteins with growth hormone activity
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2372663A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2372492A1 Cyclic amidines useful as nmda nr2b antagonists
11/16/2000CA2371902A1 Novel nucleic acids and proteins with interferon-beta activity
11/16/2000CA2371472A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000CA2371469A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2371219A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities
11/16/2000CA2371095A1 Enhanced delivery of nucleic acid-based drugs
11/16/2000CA2370838A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2370801A1 1,5-benzodiazepine derivatives as cck-a receptor agonists
11/16/2000CA2369594A1 Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000CA2366201A1 Use of selective antagonists of the .alpha.1b-adrenergic receptor for improvement of sexual dysfunction
11/15/2000EP1052286A2 Growth hormone and growth hormone releasing hormone compositions
11/15/2000EP1052259A1 Novel optically active aminopentane derivative
11/15/2000EP1052254A1 Nitrogenous heterocyclic derivatives and medicine thereof
11/15/2000EP1051995A2 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051994A2 5HT1 receptor agonists and a cox-2 inhibitor for the treatment of migraine
11/15/2000EP1051993A2 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051980A2 Dopamine transporter imaging agents
11/15/2000EP1051972A1 Nitric oxide donor composition and method for treatment of anal disorders
11/15/2000EP1051511A1 Methods of identifying modulators of kinases responsive to stress
11/15/2000EP1051490A2 Modulation of cell proliferation, methods and reagents
11/15/2000EP1051488A2 Human growth factor homologs
11/15/2000EP1051486A1 Gtpase derived from human lymph nodes that effects the morphology and cytoskeleton organization of endothelial cells
11/15/2000EP1051428A1 Human cystatin f
11/15/2000EP1051426A1 67 human secreted proteins
11/15/2000EP1051421A1 Compounds containing boron for electron microscopy and for boron neutron-capture therapy
11/15/2000EP1051416A1 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
11/15/2000EP1051415A1 Benzamide derivatives as vasopressin antagonists
11/15/2000EP1051407A1 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
11/15/2000EP1051405A2 Novel dihydroxyhexanoic acid derivatives
11/15/2000EP1051403A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/15/2000EP1051399A1 Phenylalanine derivatives useful as pharmaceutical agents
11/15/2000EP1051392A1 Adamantanecarboximidamide derivatives and their use as nmda antagonists
11/15/2000EP1051383A1 Hydroxylation activated prodrugs
11/15/2000EP1051195A1 Identification of agents that protect against inflammatory injury to neurons
11/15/2000EP1051188A1 Mucosal delivery system comprising lipophilic thrombin inhibitors
11/15/2000EP1051180A1 Phospholipids having antimicrobial activity with or without the presence of antimicrobials
11/15/2000EP1051178A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051177A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051176A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/15/2000EP1051175A1 Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli
11/15/2000EP1051173A1 Derivatives of 1,3,4-oxadiazolone
11/15/2000EP1051165A2 Mitochondria protecting agents for treating mitochondria associated diseases
11/15/2000EP1051159A1 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
11/15/2000EP1011694A4 Conditioning for allogeneic stem cell transplantation
11/15/2000EP0817795B1 Novel 4-substituted-3-peptidyl-azetidin-2-one derivatives useful as cysteine proteinase inhibitor
11/15/2000EP0717635B1 Methods for regulating gastrointestinal motility
11/15/2000EP0691847B1 Use of aspirin for the manufacture of a medicament for enhancing uterine blood perfusion
11/15/2000CN1273588A Amino acid sequences for therapeutical and prophylacticapplications to disedses due to i (clostridium difficile) toxinc
11/15/2000CN1273584A Imidazolyl-cyclic acetals
11/15/2000CN1273579A Anthranilic acid analogs
11/15/2000CN1273529A Vitronection receptor antagonist
11/15/2000CN1058487C 1,5-benzodiazepine derivatives having CCK antagoistic or agonistic activity
11/15/2000CN1058398C Chinese medicine for treatment of gynecopathy and preparation method thereof
11/15/2000CN1058390C Use of compound of benzo-thiophenes
11/14/2000US6147250 Treating diseases mediated by vascular cell adhesion molecule-1, including cardiovascular and inflammatory diseases; succinobucol
11/14/2000US6147230 Amino acid dysiherbaine
11/14/2000US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
11/14/2000US6147223 Lactacystin analogs
11/14/2000US6147211 Method for treating cyclic phosphate compound
11/14/2000US6147200 2'-O-acetamido modified monomers and oligomers
11/14/2000US6147190 Protein associated with activating cell propagation; for the treatment of a nervous system disorders; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147188 Irreversible cathepsin or calpain inhibitors
11/14/2000US6147186 Receptor agonist for treating osteoporosis
11/14/2000US6147111 Kidney, brain, and cardiovascular disorders; vasodilation
11/14/2000US6147110 Heterocyclic compounds
11/14/2000US6147109 Treating impotency; brain, cardiovascular, respiratory system and gastrointestinal disorders
11/14/2000US6147102 Topical aqueous gel suitable for relieving sympathetically maintained peripheral neuropathic pain syndrome
11/14/2000US6147099 Oxazolidinedione derivatives, their production and use
11/14/2000US6147089 Cholesteryl ester transfer protein inhibitors used to treat diseases which are exacerbated by low levels of hdl cholesterol and/or high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular
1 ... 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 ... 1564